Vir Biotechnology, Inc. — Director's Dealing 2023

Jan 26, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-01-24

Reporting Person: Pang Phillip (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-24	Common Stock	A	25406	$1.575	Acquired	169406	Direct
2023-01-24	Common Stock	A	4594	$5.175	Acquired	174000	Direct
2023-01-24	Common Stock	S	30000	$30.0019	Disposed	144000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-24	Stock Option (Right to Buy)	$1.575	M	25406	Disposed	2028-07-19	Common Stock (25406)	Direct
2023-01-24	Stock Option (Right to Buy)	$5.175	M	4594	Disposed	2029-03-11	Common Stock (4594)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

F4: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.